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Gilliam recognized subacute cutaneous lupus erythematosus (SCLE) as a lupus-specific eruption that identifies a
unique subset of lupus erythematosus. These patients were noted to have prominent photoaggravated skin disease
and often had musculoskeletal complaints, but generally did not develop significant systemic disease. SCLE patients
were later found to have other distinctive features, including the frequent presence of anti-Ro antibodies, and
enrichment for the human histocompatibility antigens (HLA) B8 and DR3. In the 13 years of published reports of SCLE
patients following the initial study by Sontheimer et al (Subacute cutaneous lupus erythematosus: a cutaneous marker
for a distinct lupus erythematosus subset. Arch Dermatol 115:1409–1415, 1979) a number of additional observations
regarding SCLE patients have been made. These have included the recognition that SCLE may be associated with other
rheumatic diseases, and that photoactive medications may induce lesions of SCLE. Areas of controversy concerning
SCLE include conflicting studies regarding the histopathology of SCLE as compared to discoid lupus erythematosus
(DLE), as well as the frequency of detection of anti-Ro antibodies in SCLE patients. Recent interesting studies of SCLE
include a description of a unique pattern of immunoglobulin G (IgG) deposition on direct immunofluorescence,
which may indicate the binding of anti-Ro antibodies to keratinocytes in vivo. J Invest Dermatol 100:2S-8S, 1993
Two very prominent contributions to dermatology by Gilliam are
his classification of cutaneous lesions in patients with lupus
erythematosus [1] and particularly his recognition of subacute
cutaneous lupus erythematosus (SCLE) as a lupus-specific
eruption with distinctive clinical and immunologic features
[2,3]. These clinical observations have enhanced our ability to
diagnose and treat lupus patients, and inspired basic research that
has advanced our understanding of lupus erythematosus (LE) and
general mechanisms of autoimmunity.
In 1989, Sontheimer summarized the worldwide experience
with SCLE [4] 10 years after their initial published report descri-
bing this disease [3]. He concluded that the initial impressions
regarding the clinical, serologic, and genetic homogeneity of
SCLE patients were largely supported by the world literature.
However, new findings include the association of SCLE with other
rheumatic diseases, such as Sjo¨gren’s syndrome and rheumatoid
arthritis, and association with medications such as the thiazides.
In the past two years, several reports have added further
information regarding the clinical, histopathologic, immunofluor-
escence, serologic, and immunogenetic features of SCLE patients.
Additional associated diseases and triggering medications have
been identified, and are summarized in this article. New findings
regarding the role of ultraviolet radiation in SCLE, and of possible
pathogenic mechanisms of SCLE are the subject of separate
reviews in this issue.
CLINICAL FINDINGS
As originally described by Sontheimer, Thomas, and Gilliam [3]
SCLE consists of an erythematous, nonscarring, papulosquamous
eruption occurring in a characteristic photodistribution, with
histology consistent with LE. Patients may have predominantly
psoriasiform lesions, annular lesions, or a combination of these
(Figs 1 and 2). A pityriasiform morphology has also been described.
Lesions may result in pigmentary changes and telangiectasia, but
characteristically do not result in dermal atrophy or scarring.
Examination of the morphology of individual lesions reveals that
the scale is less adherent than that typically seen in discoid lupus
erythematosus (DLE). Follicular plugging is generally absent. In
annular lesions, the central, less active areas may show a grayish
hypopigmentation as well as telangiectasia. The border of annular
lesions may develop vesiculation or crusting, due to intense basal
cell degeneration. With resolution, pigmentary changes, particu-
larly hypopigmentation, may be apparent. Patients with persistent
vitiligo-like changes have been described [4]. The distribution of
SCLE lesions is primarily in sun-exposed areas, with the upper back
and chest, dorsal arms, forearms, and lateral neck the most
frequent sites of involvement. On occasion, lesions are seen on the
face, scalp, and lower extremities.
Several investigators have compared the disease features of
patients with papulosquamous and annular SCLE, but generally
have not identified significant differences between these mor-
phologic subtypes of SCLE. Sontheimer et al noted that direct
immunofluorescence was positive more frequently in papulo-
squamous (88%) versus annular lesions (29%) [3]. Patients with
annular SCLE have anti-Ro antibodies and the HLA-DR3
phenotype more often than SCLE patients with papulosquamous
lesions [5,6]. A recent study of 11 SCLE patients found that SCLE
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patients with annular lesion morphology were more likely to be
hypocomplementemic, to have circulating immune complexes,
and to have positive cutaneous immunofluorescence [7]. They
concluded that SCLE patients with annular lesions may be at risk
for more severe disease. In contrast to these findings, Sontheimer
pointed out that all five of 47 SCLE patients with renal disease in
their follow-up study had the papulosquamous variant of SCLE
[4]. Thus, one cannot yet determine if lesional morphology assists
in the identification of SCLE patients likely to develop severe
systemic complications of LE.
Variations in the clinical presentation of SCLE patients include
toxic epidermal necrolysis-like changes [8] and exfoliative
erythroderma [9].
Additional LE-specific eruptions have been reported in SCLE
patients. In the initial paper by Sontheimer et al, 19% of SCLE
patients also had typical DLE lesions, usually localized to the scalp
and often preceding the onset of SCLE [3]. In their follow-up study,
15% of SCLE patients had DLE lesions, and 15% had lesions of
acute cutaneous lupus erythematosus (ACLE) [10]. Not surprisingly,
those SCLE patients with outbreaks of ACLE had more significant
systemic disease, including nephritis. Although most studies have
reported other LE-specific eruptions in only a small percentage of
SCLE patients, a few have reported higher frequencies of DLE
(52%) [11] and ACLE (100%) [12]. In the latter study, none of the
SCLE patients, all of whom had ACLE, had detectable renal disease
at the time of the study. Thus, the importance of ACLE lesions in
SCLE patients deserves further study, as clinicians seek clues to
identifying SCLE patients at risk for significant systemic illness.
LE non-specific skin lesions have also been reported in SCLE
patients, generally occurring in only a minority of patients; however,
mucous membrane lesions were reported in up to 44% [12], alopecia
in as many as 78% [12], livedo reticularis in 22% [3], periungual
telangiectasia in up to 51% [13], vasculitis in 12% [13], Raynaud’s
phenomenon in up to 30% [11], and sclerosis in 7% [3]. An
interesting finding in one SCLE patient was gradual replacement of
SCLE lesions with plaque-type morphea lesions [14].
While conducting a study of lupus erythematosus patients, we
found that some patients referred as SCLE actually had DLE. This
emphasizes the occasional difficulty in distinguishing these two
groups clinically. It is particularly important to distinguish DLE
from SCLE in studies characterizing the clinical, histologic,
serologic, and immunogenetic features of lupus patients. We
found two situations where DLE patients were incorrectly
diagnosed as SCLE. These included DLE patients with photo-
distributed lesions (Figs 3 and 4) and DLE patients with anti-Ro
antibodies. Attention to the morphologic detail of individual
lesions, particularly noting the absence of follicular plugging,
adherent scale, and evidence of scarring or dermal atrophy in
SCLE, should allow for differentiation of DLE from SCLE lesions in
nearly all cases. In addition, it was sometimes a challenge to
Figure 1. Annular lesions of SCLE. (Photo courtesy of James E. Fitzpatrick, M.D.)
Figure 2. A) Papulosquamous lesions of SCLE. B) Close inspection of
papulosquamous lesions shows scaly, erythematous papules and plaques, and
no evident follicular plugging. (Photos courtesy of Scott D. Bennion, M.D.)
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make the correct diagnosis in patients with early DLE lesions
where scarring had not yet developed. Preliminary findings from
our study suggest that induration may be a particularly helpful
feature in discerning early DLE lesions from SCLE lesions [15].
With regard to systemic disease in SCLE patients, Sontheimer
noted in his decade’s perspective that their initial impressions
regarding the generally good prognosis in SCLE patients were
supported by the majority of published reports [4]. Additional
reported cases since 1989 have provided further support for this.
Drosos et al reported 27 patients with SCLE, 78% of whom met
criteria for systemic lupus erythematosus (SLE), with CNS disease
found in 15%, but renal disease in none. This particular group of
SCLE patients were distinctive in that 85% had exclusively
papulosquamous SCLE lesions [11]. None of the 13 patients with
SCLE reported by Johansson-Stephansson et al had renal or CNS
involvement [16]. Although these reports support the overall
favorable course of disease in SCLE patients, it must be
emphasized that a few patients will experience significant extra-
cutaneous disease [17]. The importance of determining features
that identify SCLE patients at risk for severe systemic disease has
been emphasized by Sonth-eimer [4] and continues to be a
challenge in clinical research.
HISTOPATHOLOGIC FINDINGS
The histopathologic findings of SCLE were described in the initial
article by Sontheimer et al as hydropic degeneration of the
epidermal basal cell layer and a mononuclear cell infiltrate
around dermal blood vessels and appendages. However, in
contrast to DLE, the infiltrate was said to be mononuclear-cell
poor, and also follicular dilation, hyperkeratosis, and plugging
were much less prominent than that seen in DLE. Thus, they
found the histopathologic changes of SCLE to be similar to those
of DLE qualitatively, differing only in degree [3]. Other
histopathologic findings reported in lesions of SCLE include
dermal-epidermal separation due to marked basal cell degenera-
tion [4,6,18,19], and accumulation of acid muco-polysaccharides
[16].
An issue that has not yet been resolved is the question of
whether SCLE can be distinguished from other LE-specific
eruptions on the basis of routine histology. A histopathologic
study by Bangert et al found that SCLE and DLE lesions could be
distinguished histologically in 82% of specimens [20], They
reported that DLE lesions had substantially more hyperkeratosis,
basement-membrane thickening, follicular plugging, and super-
ficial and deep inflammatory cell infiltrate, whereas SCLE
biopsies had more epidermal atrophy. This paper provided
evidence that brought into question the long-held belief that
subsets of cutaneous LE could not be distinguished histologically.
The findings of Bangert et al [20] were not supported by two
subsequent reports. Jerdan et al found that separation of DLE and
SCLE by routine histology was not possible in about half of the
specimens they reviewed. [21]. They noted that pilosebaceous
atrophy was the only distinct significant predictor of DLE versus
SCLE. The SCLE patients in this study were unusual in that only
seven of 26 had anti-Ro antibodies. Jessop et al also reported
preliminary results of a similar comparative histologic study,
noting they found no marked differences between the clinical
subsets of LE. Interestingly, they also noted that their specific
histologic findings in DLE differed markedly from those reported
by Jerdan et al [22]. Possible explanations for such disparate
results were not offered in this brief report. In contrast to these
latter two studies, we reported that DLE and SCLE could be
separated reliably in 82% of specimens [23], using criteria similar
to those reported by Bangert et al [20]. Prominent hyperkeratosis
and a deeper, denser mononuclear cell infiltrate in the dermis
were the findings that were characteristic of DLE versus SCLE in
this study [23].
CUTANEOUS IMMUNOFLUORESCENCE FINDINGS
Although the majority of SCLE patients have been reported to have
granular deposition of immunoreactants at the dermal-epidermal
junction in lesional skin, it has been noted that these deposits are
found considerably less often than in lesions of DLE [3]. A minority
of SCLE patients have been reported to have immunoreactant
Figure 3. Photodistributed DLE lesions.
Figure 4. Close inspection of lesions of photodistributed DLE reveals scarring
and follicular plugging, features that separate DLE from SCLE.
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deposition in non-lesional skin [3,6,16]. In addition, a unique
pattern of immunofluorescence has been reported in SCLE patients.
‘‘Dust-like particles’’ of IgG deposition in the epidermis, the
subepidermal region, and the dermal cellular infiltrates in 32% of
biopsies from SCLE lesions were reported by Nieboer et al [24].
This pattern of staining was not seen in specimens from DLE and
SLE patients. These deposits did not correlate with the presence of
anti-Ro antibodies in their study. We have reported preliminary
findings of a similar paniculate deposition of IgG in the epidermis
of SCLE lesions (Fig 5) and have also noted such staining in the
non-lesional skin of SCLE patients. All of the SCLE patients in our
preliminary study had anti-Ro antibodies [15]. We, too, did not
find this pattern of staining in patients with DLE or in SLE patients
without cutaneous LE. This interesting immunofluorescent pattern
was reported in previous animal studies. Lee et al found similar
paniculate epidermal staining in human skin grafted onto
immunosuppressed mice, after human anti-Ro antibodies were
injected [25]. Such staining was not seen after injection of normal
sera, and could be blocked by removal of the anti-Ro antibodies.
This suggests that the paniculate epidermal deposition of IgG may
indicate the binding of anti-Ro antibodies. Although these findings
suggest anti-Ro antibodies may be involved in the pathogenesis of
SCLE lesions, their presence in non-lesional skin indicates that
additional factors must be important in inducing skin lesions.
SEROLOGIC FINDINGS
The majority of SCLE patients have been reported to have anti-Ro
antibodies, in most published series [4]. Reports since Sonthei-
mer’s 10-year review further support this finding [7,11,16]. When
more sensitive techniques, such as the enzyme-linked immuno-
sorbent assay (ELISA), are used, the frequency of anti-Ro
antibodies is higher [26]. Table I compares several reported
frequencies of anti-Ro antibodies in SCLE patients, using different
techniques. Intensive investigations into the nature of the Ro
antigen complex are ongoing and are the subject of a separate
review in this issue.
IMMUNOGENETICS
Sontheimer and co-workers have reported an increase in the
human histocompatibility antigen (HLA) DR3 in SCLE patients,
and particularly in those patients with the annular subtype of
lesions [5,27]. Most other groups have found that 50% or more
of SCLE patients have the HLA-DR3 phenotype [6,16,28]; how-
ever, some have reported lower frequencies [11,29]. Additional
immunogenetic findings include an increased frequency of C4
null alleles [16] and an increase in HLA-DR2 [16,30].
ASSOCIATED DISEASES
SCLE lesions have been reported in association with a variety of
other systemic diseases — rheumatic and non-rheumatic. These
associated diseases have been reported to precede, coincide with,
or follow the onset of SCLE.
Rheumatic diseases associated with SCLE include Sjo¨gren’s
syndrome [4,28,30] and rheumatoid arthritis [31,32]. The per-
centage of SCLE patients with associated Sjo¨gren’s syndrome has
been variable, with one series reporting only 3% [33] and a
recent series with 18% of SCLE patients so affected [11]. Just how
commonly one finds Sjo¨gren’s syndrome along with lesions of
SCLE overall is unknown. However, such an association would be
very important to recognize in the evaluation of patients with
SCLE, as significant systemic disease has been reported in these
patients [34].
SCLE lesions have also been reported in association with
complement abnormalities, including inherited deficiency of the
Figure 5. Direct immunofluorescence exam demonstrating paniculate
epidermal deposition of IgG in subacute cutaneous lupus erythematosus.
(Magnification  400.) The dermal-epidermal junction is marked with
arrows.
Table I. Frequency of Anti-Ro Antibodies in SCLE
Patients
Authors Reference Year n Percent Anti-Ro + Methoda
Sontheimer et al [51] 1982 27 62 DD, CIE
Hymes et al [87] 1986 21 95 DD
Callen et al [13] 1986 49 29 DD
Weinstein et al [89] 1987 17 59 CIE
Lieu et al [90] 1988 14 93 ELISA
McHugh et al [91] 1988 8 38 DD
Callen, Klein [29] 1988 82 41 DD
Provost et al [28] 1988 10 100 DD, ELISA
Mooney, Wade [88] 1989 5 80 DD
Johansson et al [16] 1989 13 54 DD
Drosos et al [11] 1990 23 70 CIE
Provost et al [26] 1991 31 59 DD
Provost et al [26] 1991 31 71 ELISA
Bielsa et al [92] 1991 56 46 CIE
aDD, double immunodiffusion; CIE, counterimmunoelectrophoresis;
ELISA, enzyme-linked immunosorbent assay.
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third complement component [35], C2 deficiency [36–38], C4
deficiency [39], and hereditary angioedema [40].
Isolated case reports have described SCLE lesions in patients
with diagnoses of porphyria cutanea tarda [41], Sweet’s syndrome
[42,43], malabsorption [44], and gluten-sensitive enteropathy [45].
In addition, SCLE lesions have been reported with a variety of
malignancies, including lung cancer [46], gastric cancer [47],
breast cancer [48,49], and malignant melanoma [50].
DRUG ASSOCIATIONS
A number of prescribed medications have been associated with
the onset or exacerbation of SCLE lesions. The most frequently
associated drugs are the thiazides [4,51–54]. Other medications
associated with SCLE lesions include piroxicam [55], penicilla-
mine [4], glyburide [4], aldactone [56], chrysotherapy [57], and
griseofulvin [58]. Eruptions suggestive of SCLE were also reported
with procainamide [59] and oxyprenolol [60]. These reports
emphasize the need for a thorough medication history in the
evaluation of patients with SCLE. Many of these patients with
medication-induced SCLE had anti-Ro antibodies. An interesting
study by Lieu et al [61] suggests that anti-Ro antibodies in patients
with drug-induced SCLE recognize different epitopes of the 60-kD
Wil-2 Ro protein than do anti-Ro antibodies from patients with
SCLE not associated with medications. Further serologic and
immunogenetic studies of patients with drug-induced SCLE may
advance our understanding of pathogenic mechanisms in this
interesting disease.
TREATMENT
Specific treatment of subacute cutaneous lupus erythematosus
has been recently reviewed [62]. Education regarding the current
understanding of lupus erythematosus in general and SCLE in
particular is important in the initial treatment of SCLE patients.
Lay literature dealing specifically with SCLE is not readily
available; however, the Lupus Foundation distributes brochures
that may be pertinent to SCLE patients, including topics such as
cutaneous LE, antimalarial drugs, and general information about
LE. An explanation of the differences between groups of lupus
patients, and reassurance that most SCLE patients thus far have
not had significant systemic disease are important concepts to
communicate. However, it is also critical that SCLE patients know
how to access medical care expeditiously in the event that
systemic symptoms develop, and that they are aware of the signs
and symptoms of SLE and that serious manifestations of SLE
occasionally develop in SCLE patients and require prompt
medical attention. In addition, discussion of factors that may
aggravate LE, with emphasis on avoiding these, is important.
These include natural sunlight as well as artificial ultraviolet
radiation in both commercial parlors [63] and physicians offices
(PUVA) [64,65]. Broad-spectrum sunscreens and sun-protective
measures should be strongly encouraged as a foundation of the
treatment plan. This may need to be reemphasized at each
follow-up visit. Patients receiving systemic medications for
control of SCLE may believe that these drugs obviate the need
for continued sun protection. However, lesions of cutaneous LE
have been induced with artificial radiation in patients on systemic
therapy [66,67]. The efficacy of a broad spectrum sunscreen in six
patients with SCLE was documented recently [68]. Some SCLE
patients have reported that their skin disease worsens with heat
[4]; thus excessive exposure to heat should be avoided if possible.
Medications that can induce or aggravate lesions of SCLE, most
commonly the thiazide diuretics, should be avoided. There is
experimental evidence that estrogens may enhance expression
of the Ro protein on the surface of keratinocytes [69]. Also,
estrogen-containing oral contraceptives have been associated
with flaring in SLE [70]. To date, there are no clinical studies
evaluating the effects of estrogen or progesterone in SCLE
patients; however, flaring of SCLE during pregnancy has been
noted [71]. Thus, it seems prudent to avoid estrogen-containing
medications when possible. Many patients report that stress
aggravates their disease, suggesting that attention to general
health, including diet, rest, and relaxation, may also be
beneficial.
Therapy with moderate to potent topical steroids is often
helpful in lesions of SCLE. Close observation for signs of atrophy
when potent topical steroids are used is important, as untreated
SCLE lesions do not result in significant atrophy. The widespread
distribution of SCLE lesions may preclude treatment with potent
topical steroids, due to risk of systemic effects as well as excessive
expense.
Antimalarial therapy is the systemic therapy of choice when
more conservative therapy fails, and has been reported to control
80–90% of SCLE patients [4]. Hydroxychloroquine sulfate and/or
quinacrine hydrochloride are the most commonly used antimalar-
ials for cutaneous LE. Response to treatment may require weeks to
a few months. Systemic steroids have been used in SCLE patients
with severe disease, or to control disease while slower-acting
agents, such as antimalarials, are begun. However, it has been
emphasized that such treatment should be limited to brief periods
to avoid serious side effects.
There are a number of additional systemic treatments that have
been reported to be of benefit in SCLE patients. These include
dapsone [38,72,78], isotretinoin [74-77], etretinate [78,79],
acitretin [80], clofazimine [81,82], and thalidomide [83]. In
addition, azathioprine, cyclophosphamide, methotrexate, plas-
mapheresis [84], and pulse methylprednisolone [85] have been
used in severe refractory cases of SCLE. A recent report describes
short-term benefits using recombinant interferon alpha 2A [86].
Because these latter agents have not been formally evaluated for
safety and efficacy in large groups of SCLE patients, careful
consideration of the expected benefits and possible risks of such
treatment should be given. It should be remembered that SCLE
patients most often follow a relatively benign course.
SUMMARY
Gilliam’s astute clinical observation that SCLE is a distinctive
lupus-specific eruption that identifies a relatively homogeneous
subgroup of LE patients has generated over a decade of
worldwide interest and study. The majority of published reports
support the initial impressions of Gilliam and Sontheimer
that SCLE patients typically have prominent cutaneous and
musculoskeletal complaints, but generally are spared the
serious systemic complications of SLE. Later observations of the
unique immunogenetic features of SCLE patients have generated
many new areas of research. These include studies of the
autoantigen complex to which SCLE patients antibodies are
directed, and the possible relationship of these anti-Ro antibodies
to the pathogenesis of disease. The significance of Gilliam’s
contributions to our specialty is evident in the extent of basic
research that has evolved from the clinical observations of this
exceptional man.
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